Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals Balance Sheet

Financials in millions AUD. Fiscal year is January - December.

Year	2023	2022
Cash & Equivalents	123.24	116.33
Cash & Cash Equivalents	123.24	116.33
Cash Growth	5.94%	-
Receivables	64.78	39.35
Inventory	17.31	8.48
Other Current Assets	19.52	9.07
Total Current Assets	224.85	173.23
Property, Plant & Equipment	23.17	12.03
Long-Term Investments	12.26	-
Goodwill and Intangibles	116.99	65.79
Other Long-Term Assets	21.04	4.3
Total Long-Term Assets	173.45	82.12
Total Assets	398.3	255.35
Accounts Payable	81.7	49.52
Current Debt	1.56	0.64
Other Current Liabilities	74.15	35.4
Total Current Liabilities	157.41	85.56
Long-Term Debt	15.89	9.81
Other Long-Term Liabilities	76.1	79.99
Total Long-Term Liabilities	91.98	89.79
Total Liabilities	249.39	175.35
Total Debt	17.45	10.45
Debt Growth	67.00%	-
Comprehensive Income	-263.67	-272.82
Shareholders' Equity	148.91	80.01
Net Cash / Debt	105.79	105.88
Net Cash / Debt Growth	-0.09%	-
Working Capital	67.44	87.68

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).